Rebecca L Olin MD
Hematologic Oncology
Assistant Professor, Medicine, UCSF School of Medicine
Join to View Full Profile
400 Parnassus AveBox 0324San Francisco, CA 94143
Phone+1 415-353-2063
Dr. Olin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2006 - 2009- University of Pennsylvania Health SystemResidency, Internal Medicine, 2003 - 2006
Perelman School of Medicine at the University of PennsylvaniaClass of 2003
Certifications & Licensure
CA State Medical License 2009 - 2026
PA State Medical License 2003 - 2010
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Targeted, Dose-Escalation Busulfan-Etoposide as Prep Regimen Start of enrollment: 2009 Nov 01
- Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Start of enrollment: 2011 Sep 01
- Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Start of enrollment: 2011 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- Novel Composite Health Assessment Risk Model for Older Allogeneic Transplant Recipients: BMT-CTN 1704.Mohamed L Sorror, Wael Saber, Brent R Logan, Nancy L Geller, Anna Bellach
Blood Advances. 2025-03-18 - US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or Chimeric Antigen Receptor T Cell Therapy: An American Society for T...Pashna N Munshi, Rebecca L Olin, Sarah Wall, Shannon R McCurdy, Taha Al-Juhaishi
Transplantation and Cellular Therapy. 2025-02-15 - 3 citationsBeat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.Fieke W Hoff, William G Blum, Ying Huang, Rina Li Welkie, Ronan T Swords
Blood Advances. 2024-10-22
Abstracts/Posters
- Incidence of Serious Adverse Events, Pneumonitis, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphom...Rebecca L. Olin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndr...Rebecca Olin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative NeoplasmsRebecca L. Olin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Friday Scientific Workshop on Hematology and Aging: From Bleeding Disorders to Malignant Hematology61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Cognitive Impairment Is Associated with Inferior Survival and Increased Non-Relapse Mortality in Older Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients: A...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Aging and Hematologic Disorders: Exploring the Evidence61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
